Mads Daugaard

Company: Rakovina Therapeutics
Job title: President & Chief Scientific Officer
Seminars:
Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma 9:00 am
kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibitionRead more
day: Day One